EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Influence of Baseline Itch Severity on Treatment Outcomes With Difelikefalin in Adults With Moderate‐to‐Severe Pruritus Receiving Maintenance Haemodialysis: An Exploratory Analysis

Kieran McCafferty, Thilo Schaufler, Pablo Molina, Murray Lowe, Warren Wen, Daniel E Weiner

Journal of Renal Care · 2025-06 · 51 (2)

DOI: 10.1111/jorc.70017 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Renal Care, online erschienen am 06.05.2025. Verfasst von Kieran McCafferty und 5 weiteren Autor:innen. Beteiligte Einrichtung: Barts Health NHS Trust, London, UK. Hauptthemen laut MEDLINE: Pruritus, Renal Dialysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funding for the overall phase 3 trial, Study 3105 (NCT03998163), was provided by Cara Therapeutics. This exploratory subgroup analysis from Study 3105 was fund….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Difelikefalin is well‐tolerated and reduces itch among adults undergoing haemodialysis (HD), with chronic kidney disease‐associated pruritus (CKD‐aP).

Objective

This study aims to explore the influence of baseline itch severity on difelikefalin treatment outcomes.

Design

Study 3105 (NCT03998163) was a 12‐week, phase 3, single‐arm, open‐label trial assessing safety and effectiveness of difelikefalin 0.5 µg/kg. We report key endpoints from 3105 by baseline itch severity, determined using the Worst Itching Intensity Numerical Rating Scale (WI‐NRS [moderate: WI‐NRS < 7; severe: WI‐NRS ≥ 7]).

Participants

Adult participants undergoing maintenance HD ( n = 222) with mild‐to‐moderate CKD‐aP (WI‐NRS score ≥ 5 at baseline).

Measurements

The primary endpoint of 3105 was safety; secondary endpoints included reduction in itch intensity (WI‐NRS), and improvements in itch‐related quality of life (QoL; 5‐D itch scale) and sleep quality (Sleep Quality Numerical Rating Scale).

Findings

Mean (SD) age was 57.1 (13.3) years; mean (SD) baseline WI‐NRS scores were 6.0 (0.5) and 8.3 (0.9) for participants with moderate ( n = 70/222) or severe ( n = 152/222) itch, respectively. No treatment‐related deaths occurred, and there were no safety concerns according to baseline itch severity. By week 12, both groups reported residual ‘mild itch’ according to mean (SD) WI‐NRS scores (moderate: 2.9 [2.2]; severe: 3.1 [2.3]). Approximately one in four participants demonstrated ‘complete response’ in itch reduction (moderate: 27.1%; severe: 25.0%). Clinically relevant improvements in itch‐related QoL and sleep quality occurred among both subgroups.

Conclusions

Difelikefalin was well‐tolerated and effective in reducing itch in participants with moderate and severe baseline itch, supporting its broad use in a range of individuals on HD with CKD‐aP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PruritusRenal DialysisHumansMaleFemaleMiddle AgedSeverity of Illness IndexAgedTreatment OutcomeAdultQuality of LifeRenal Insufficiency, Chronic

Stichwörter der Autor:innen

difelikefalinhaemodialysispruritusquality of lifetolerability

Autor:innen und Institutionen

  • Barts Health NHS Trust, London, UK.
  • CSL Vifor, Glattbrugg, Switzerland.
  • Department of Nephrology, FISABIO, Hospital Universitari Dr Peset, Universitat de València, València, Spain.
  • Cara Therapeutics, Stamford, Connecticut, USA.
  • William B. Schwartz, MD, Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.

Förderung

  • Funding for the overall phase 3 trial, Study 3105 (NCT03998163), was provided by Cara Therapeutics. This exploratory subgroup analysis from Study 3105 was fund…

Zitieren

APA

McCafferty, K., Schaufler, T., Molina, P., Lowe, M., Wen, W., & Weiner, D. E. (2025). Influence of Baseline Itch Severity on Treatment Outcomes With Difelikefalin in Adults With Moderate‐to‐Severe Pruritus Receiving Maintenance Haemodialysis: An Exploratory Analysis. Journal of Renal Care, 51(2). https://doi.org/10.1111/jorc.70017

Vancouver

McCafferty K, Schaufler T, Molina P, Lowe M, Wen W, Weiner DE. Influence of Baseline Itch Severity on Treatment Outcomes With Difelikefalin in Adults With Moderate‐to‐Severe Pruritus Receiving Maintenance Haemodialysis: An Exploratory Analysis. Journal of Renal Care. 2025;51(2). doi:10.1111/jorc.70017

BibTeX
@article{McCafferty2025,
  author = {McCafferty, Kieran and Schaufler, Thilo and Molina, Pablo and Lowe, Murray and Wen, Warren and Weiner, Daniel E},
  title = {Influence of Baseline Itch Severity on Treatment Outcomes With Difelikefalin in Adults With Moderate‐to‐Severe Pruritus Receiving Maintenance Haemodialysis: An Exploratory Analysis},
  journal = {Journal of Renal Care},
  year = {2025},
  volume = {51},
  number = {2},
  doi = {10.1111/jorc.70017}
}
Kostenlos starten →